18th June 2018

Award-winning digital health company launches latest version of flagship software

Aparito, the leading provider of remote patient monitoring and digital health technology supporting rare diseases, has announced the launch of its very latest build of its core product – Atom 5, Helium edition.

Aparito’s latest addition to the company’s product suite makes its debut supporting a paediatric epilepsy study in Cape Town. Supported by the Newton Fund and the South African Medical Research Council, the study will utilise the Atom 5 platform to collect and analyse patient generated data outside of the hospital as part of a treatment optimisation and precision medicine initiative.

The release of this latest edition provides Aparito’s customers with the same easy to use solution with even more features and configuration options. Dr. Ian Radford, Aparito Chief Technology Officer, said: “Helium is a huge leap forward in how the platform can now be setup to support any study design, for any disease or healthcare treatment pathway. Patient Reported Outcome questionnaires can be setup in minutes and configured to cope with different frequencies of distribution and responses. Further, the entire core system is 100% configurable. This allows the customer to select which dimensions of data they wish to capture and to specify exactly which individual fields are desirable. We also found time to add a new wearable device to the collection which now allows us to sample heart rate readings much more frequently.”

Aparito provide a regulated software platform, including wearable devices and disease-specific mobile apps, to provide remote patient monitoring outside of the hospital environment. This delivers meaningful, relevant, and real-time data between patients and clinicians in a way that actively supports and enhances diagnosis, treatment and drug development. Patients are rapidly on-borded easily through a QR code and the Atom 5 app will remind patients to record medication, events, Patient Reported Outcomes and visits on a daily basis.

Aparito’s core offering is developed in accordance with the international standard ISO 13485 and received a CE mark for a Class 1 Medical Device from the European authorities in March of this year. In attaining this CE mark, customers can use the Aparito technology with confidence in a range of trial and routine care settings where regulatory compliance is essential.

To learn more about Aparito visit www.aparito.com and follow on Twitter @aparitohealth